Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Sinovac Biotech Ltd., Beijing, China
Research Article
A Randomized Placebo-controlled Trial to Evaluate the Efficacy, Immunogenicity and Safety of an Inactivated COVID-19 Vaccine (CoronaVac®) in Children and Adolescents
Author(s): Nicolás MS Gálvez, Qiangian Xin, Katia Abarca, María J Álvarez-Figueroa, Sanet Aspinall, Susan M Bueno, José V González-Aramundiz, Nicole Le Corre, Weining Meng, Xing Meng, Cecilia Perret, Jorge A Soto, Gang Zeng and Alexis M Kalergis*
Background: The inactivated COVID-19 vaccine developed by Sinovac (CoronaVac®) has been shown to effectively prevent
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. Phase I/II clinical trials in healthy adults aged
18-59 and over 60 showed good safety and immunogenicity in China. Phase III clinical trials are currently being carried out
in Brazil, Indonesia, Chile, and Turkey. The WHO approved CoronaVac® for emergency use in adults on June 01, 2021. A
Phase I/II clinical trial in children and teenagers aged 3-17 was performed in China in 2020.
Methods: This is a global multi-center, randomized, double-blinded, and placebo-controlled phase III clinical trial that aims to
assess the safety, efficacy, and immunogenicity of CoronaVac® in the pediatric population. .. View More»
DOI:
10.35248/2167-0870.22.12.497